Interview with Aris Persidis, President of BioVista

29-04-2021

As patent protections expire, drug repositioning has become a matter of intense interest. Aris Persidis founded Biovista in 2005 and has focused on using artificial intelligence to match drugs against any and all mechanisms, pathways, diseases and clinical outcomes. 


LSIPR